Do analysts prefer CRVL or CSTL?

Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 26.85%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Castle Biosciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80

Does the media refer more to CRVL or CSTL?

In the previous week, Castle Biosciences had 7 more articles in the media than CorVel. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for CorVel. CorVel's average media sentiment score of 1.79 beat Castle Biosciences' score of 0.21 indicating that CorVel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorVel 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CSTL or AVAH?

In the previous week, Castle Biosciences had 6 more articles in the media than Aveanna Healthcare. MarketBeat recorded 9 mentions for Castle Biosciences and 3 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 0.77 beat Castle Biosciences' score of 0.21 indicating that Aveanna Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aveanna Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRVA or CSTL?

In the previous week, Castle Biosciences had 7 more articles in the media than Privia Health Group. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for Privia Health Group. Privia Health Group's average media sentiment score of 0.86 beat Castle Biosciences' score of 0.21 indicating that Privia Health Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Privia Health Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CSTL or NEO?

In the previous week, Castle Biosciences had 7 more articles in the media than NeoGenomics. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.36 beat Castle Biosciences' score of 0.21 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WGS or CSTL?

In the previous week, Castle Biosciences had 3 more articles in the media than GeneDx. MarketBeat recorded 9 mentions for Castle Biosciences and 6 mentions for GeneDx. GeneDx's average media sentiment score of 0.52 beat Castle Biosciences' score of 0.21 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Castle Biosciences (CSTL) Competitors

$33.80 +0.69 (+2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$33.83 +0.03 (+0.07%)

As of 06:49 PM Eastern

Compare

CSTL vs. CRVL, AVAH, PRVA, NEO, and WGS

Should you buy Castle Biosciences stock or one of its competitors? Castle Biosciences's main competitors and comparable companies include CorVel (CRVL), Aveanna Healthcare (AVAH), Privia Health Group (PRVA), NeoGenomics (NEO), and GeneDx (WGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Castle Biosciences compare to CorVel?

CorVel (NASDAQ:CRVL) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

51.4% of CorVel shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 39.7% of CorVel shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 26.85%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Castle Biosciences had 7 more articles in the media than CorVel. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for CorVel. CorVel's average media sentiment score of 1.79 beat Castle Biosciences' score of 0.21 indicating that CorVel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorVel	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Castle Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorVel has a net margin of 11.72% compared to Castle Biosciences' net margin of -5.43%. CorVel's return on equity of 29.92% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.72%	29.92%	17.82%
Castle Biosciences	-5.43%	-4.15%	-3.45%

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$958.53M	4.28	$110.34M	$2.25	35.73
Castle Biosciences	$344.23M	2.94	-$24.16M	-$0.66	N/A

CorVel has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

CorVel beats Castle Biosciences on 10 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Aveanna Healthcare?

Castle Biosciences (NASDAQ:CSTL) and Aveanna Healthcare (NASDAQ:AVAH) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Castle Biosciences had 6 more articles in the media than Aveanna Healthcare. MarketBeat recorded 9 mentions for Castle Biosciences and 3 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 0.77 beat Castle Biosciences' score of 0.21 indicating that Aveanna Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aveanna Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aveanna Healthcare has a net margin of 10.56% compared to Castle Biosciences' net margin of -5.43%. Aveanna Healthcare's return on equity of 80.70% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Aveanna Healthcare	10.56%	80.70%	7.42%

Aveanna Healthcare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.94	-$24.16M	-$0.66	N/A
Aveanna Healthcare	$2.43B	1.11	$225.03M	$1.23	10.05

Castle Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Castle Biosciences currently has a consensus target price of $42.00, suggesting a potential upside of 26.85%. Aveanna Healthcare has a consensus target price of $14.06, suggesting a potential upside of 13.72%. Given Castle Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Castle Biosciences is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 5.3% of Aveanna Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aveanna Healthcare beats Castle Biosciences on 8 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Privia Health Group has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12B	1.30	$22.92M	$0.21	103.19
Castle Biosciences	$344.23M	2.94	-$24.16M	-$0.66	N/A

Privia Health Group has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Privia Health Group currently has a consensus price target of $31.00, suggesting a potential upside of 43.05%. Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 26.85%. Given Privia Health Group's higher possible upside, equities analysts plainly believe Privia Health Group is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Castle Biosciences had 7 more articles in the media than Privia Health Group. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for Privia Health Group. Privia Health Group's average media sentiment score of 0.86 beat Castle Biosciences' score of 0.21 indicating that Privia Health Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Privia Health Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Privia Health Group has a net margin of 1.19% compared to Castle Biosciences' net margin of -5.43%. Privia Health Group's return on equity of 3.52% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Privia Health Group	1.19%	3.52%	2.00%
Castle Biosciences	-5.43%	-4.15%	-3.45%

94.5% of Privia Health Group shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 5.7% of Privia Health Group shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Privia Health Group beats Castle Biosciences on 10 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to NeoGenomics?

Castle Biosciences (NASDAQ:CSTL) and NeoGenomics (NASDAQ:NEO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Castle Biosciences had 7 more articles in the media than NeoGenomics. MarketBeat recorded 9 mentions for Castle Biosciences and 2 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.36 beat Castle Biosciences' score of 0.21 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Castle Biosciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Castle Biosciences has a net margin of -5.43% compared to NeoGenomics' net margin of -6.77%. NeoGenomics' return on equity of -1.99% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
NeoGenomics	-6.77%	-1.99%	-1.21%

Castle Biosciences currently has a consensus target price of $42.00, indicating a potential upside of 26.85%. NeoGenomics has a consensus target price of $18.17, indicating a potential upside of 7.62%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 1.1% of NeoGenomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Castle Biosciences has higher earnings, but lower revenue than NeoGenomics. Castle Biosciences is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.94	-$24.16M	-$0.66	N/A
NeoGenomics	$727.33M	2.98	-$108.03M	-$0.40	N/A

Summary

Castle Biosciences and NeoGenomics tied by winning 8 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to GeneDx?

GeneDx (NASDAQ:WGS) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

GeneDx has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

In the previous week, Castle Biosciences had 3 more articles in the media than GeneDx. MarketBeat recorded 9 mentions for Castle Biosciences and 6 mentions for GeneDx. GeneDx's average media sentiment score of 0.52 beat Castle Biosciences' score of 0.21 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeneDx currently has a consensus price target of $90.86, indicating a potential upside of 32.43%. Castle Biosciences has a consensus price target of $42.00, indicating a potential upside of 26.85%. Given GeneDx's higher possible upside, equities research analysts plainly believe GeneDx is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.79	-$21.02M	-$3.64	N/A
Castle Biosciences	$344.23M	2.94	-$24.16M	-$0.66	N/A

Castle Biosciences has a net margin of -5.43% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Castle Biosciences	-5.43%	-4.15%	-3.45%

61.7% of GeneDx shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

GeneDx beats Castle Biosciences on 9 of the 15 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$10.45B	$7.43B	$12.93B
Dividend Yield	N/A	2.61%	2.52%	19.59%
P/E Ratio	-51.21	34.47	274.96	25.39
Price / Sales	2.89	4.64	608.73	90.53
Price / Cash	29.54	115.88	76.68	52.75
Price / Book	2.10	5.21	10.32	6.02
Net Income	-$24.16M	$315.68M	$3.49B	$380.68M
7 Day Performance	0.27%	0.56%	-2.54%	-3.01%
1 Month Performance	-4.79%	-3.65%	-6.87%	-5.59%
1 Year Performance	50.16%	10.36%	1.81%	-5.23%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	2.4232 of 5 stars	$33.80 +2.1%	$42.00 +24.3%	+48.1%	$1.03B	$357.28M	N/A	1,002	Insider Trade
CRVL CorVel	1.6512 of 5 stars	$75.84 -0.2%	N/A	+11.6%	$3.87B	$958.53M	33.71	5,239	Positive News
AVAH Aveanna Healthcare	4.2404 of 5 stars	$12.20 -1.4%	$14.06 +15.3%	+32.6%	$2.66B	$2.43B	9.91	35,500	Analyst Upgrade
PRVA Privia Health Group	3.9952 of 5 stars	$20.44 0.0%	$31.00 +51.7%	-12.7%	$2.61B	$2.12B	97.30	1,226	Positive News
NEO NeoGenomics	1.9184 of 5 stars	$16.69 -12.8%	$18.17 +8.8%	+80.0%	$2.14B	$727.33M	N/A	2,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. CRVL, AVAH, PRVA, NEO, and WGS

How does Castle Biosciences compare to CorVel?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Summary

How does Castle Biosciences compare to Privia Health Group?

Summary

How does Castle Biosciences compare to NeoGenomics?

Summary

How does Castle Biosciences compare to GeneDx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. CRVL, AVAH, PRVA, NEO, and WGS

How does Castle Biosciences compare to CorVel?

Do institutionals & insiders have more ownership in CRVL or CSTL?

Do analysts prefer CRVL or CSTL?

Does the media refer more to CRVL or CSTL?

Is CRVL or CSTL more profitable?

Which has higher earnings & valuation, CRVL or CSTL?

Which has more risk and volatility, CRVL or CSTL?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Does the media refer more to CSTL or AVAH?

Is CSTL or AVAH more profitable?

Which has preferable valuation and earnings, CSTL or AVAH?

Which has more volatility & risk, CSTL or AVAH?

Do analysts rate CSTL or AVAH?

Do insiders & institutionals have more ownership in CSTL or AVAH?

Summary

How does Castle Biosciences compare to Privia Health Group?

Which has better earnings and valuation, PRVA or CSTL?

Which has more volatility & risk, PRVA or CSTL?

Do analysts prefer PRVA or CSTL?

Does the media prefer PRVA or CSTL?

Is PRVA or CSTL more profitable?

Do insiders and institutionals have more ownership in PRVA or CSTL?

Summary

How does Castle Biosciences compare to NeoGenomics?

Does the media refer more to CSTL or NEO?

Which has more risk and volatility, CSTL or NEO?

Is CSTL or NEO more profitable?

Do analysts prefer CSTL or NEO?

Do institutionals & insiders hold more shares of CSTL or NEO?

Which has preferable earnings & valuation, CSTL or NEO?

Summary

How does Castle Biosciences compare to GeneDx?

Which has more volatility and risk, WGS or CSTL?

Does the media prefer WGS or CSTL?

Do analysts prefer WGS or CSTL?

Which has higher earnings and valuation, WGS or CSTL?

Is WGS or CSTL more profitable?

Do insiders & institutionals believe in WGS or CSTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools